Clinical trial · Interventional
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
The Efficacy and Safety of Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) Regimen in High-risk Treatment-naive Patients with Follicular Lymphoma
NCT06549335CI-TRIAL-00081604not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in high-risk treatment-naive patients with follicular lymphomas
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
- interventionNames
- Drug: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
Primary outcomes (1)
- measure
- Objective response rate (ORR)
- timeFrame
- At the end of Cycle 6 (each cycle is 28 days)
- description
- Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria
Secondary outcomes (5)
- measure
- Complete response rate (CR)
- timeFrame
- At the end of Cycle 6 (each cycle is 28 days)
- description
- Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification 2. Treatment naive 3. Age ≥ 18 years 4. Indications for treatment confirmed 5. Identified as high-risk group by Follicular Lymphoma International Prognostic Index 2 (FLIPI2) at enrollment 6. Must has measurable lesion in CT or PET-CT prior to treatment 7. Considered suitable for ZGR regimens 8. Informed consented Exclusion Criteria: * Transformed follicular lymphoma or 3B follicular lymphoma; * HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive * Any drug contraindication in the treatment plan * Pregnant or lactating women * Patients judged by other researchers to be unsuitable for inclusion in the study
References
Publications (0)
Data not yet available
No reference posted for this study.